



On-line Table 1: Correlation of outcome assessment with stem cell intervention parameters

Parameters	Good Outcome (n = 8) (Mean)	Poor Outcome (n = 2) (Mean)	P Value
Poststroke day of intervention	9.88 ± 2.748	10 ± 2.8	.956
Stem cell harvest volume (mL)	117 ± 6.8	117 ± 11.31	.887
Infusate volume (mL)	5 ± 0	5 ± .354	.135
Total nucleated cells	$1.12 \times 10^9 \pm 4.58 \times 10^8$	$6.15 \times 10^8 \pm 2.1 \times 10^7$	.179
Mononucleated cells	$2.08 \times 10^9 \pm 4 \times 10^8$	$4.3 \times 10^8 \pm 4.2 \times 10^7$	.593
CD34 cell count	$1.1 \times 10^7 \pm 4.1 \times 10^6$	$5.6 \times 10^6 \pm 2.7 \times 10^6$	.104
CD34 cell (%)	1.02 ± .28	.85 ± .35	.47
Viability (%)	93.9 ± 3.1	96 ± 0	.118



ON-LINE FIGURE. Clinical outcomes. Boxplots show the change in the modified Rankin Scale (A) and Barthel index (B) during the 6-month follow-up.

On-line Table 2: Comparison with the previous studies

Study	Design	Study Population	Follow-Up	Primary Outcome (Safety)	Secondary Outcome (Clinical Improvement)	Mean NIHSS Preprocedure	Mean Stem Cell Dose	Route of Delivery/Day of Implantation Poststroke
Moniche et al ⁵	Nonrandomized, controls, blinded	20	6 mo	No mortality/stroke/tumor formation (2 patients had seizures at 3 mo)	mRS ≤ 2 (20% vs 0 in controls) $P = .47$	15.6	1.59×10^8	Intra-arterial/5–9 days
Battistella et al ⁶	Nonrandomized, no blinding, no controls	6	6 mo	No complications	Improved NIHSS, BI, and mRS	9.2	3.05×10^8	Intra-arterial/up to 90 days
Suárez-Monteagudo et al ⁷	Nonrandomized, no blinding, no controls	5	12 mo	No complications	Mild neurophysiologic improvement	Not available	34×10^6	Stereotactic/5 yr
Savitz et al ⁸	Nonrandomized, no blinding, no controls	10	6 mo	No complications (1 mortality due to pulmonary embolism)	mRS reduction by 1 point in all patients	13	1×10^7 /kg	Intravenous/24–72 hr
Freidrich et al ⁹	Nonrandomized, no blinding, no controls	20	6 mo	No complications	Good clinical outcome in 40% of cases	17	22×10^7	Intra-arterial/3–7 days
Banerjee et al ¹⁴	Nonrandomized, no blinding, no controls	5	6 mo	No complications	Improved mRS and NIHSS, reduced infarct volume	10.4	2.2×10^6 (CD34+ cells)	Intra-arterial/within 7 days
Present study	Prospective, randomized, blinded	20	6 mo	No complications (1 mortality, non-procedure-related)	Good clinical outcome in 80% of stem cell cases vs 40% of controls	10.5	1×10^7	Intra-arterial/7–15 days